Powered by
GeNeuro Publishes the English Version of Its 2016 Reference Document

Regulatory News:

GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis, publishes the English version of its 2016 Reference Document, which has been filed on April28,2017,with the "Autorité des Marchés Financiers (AMF)".

This document is available to the public free of charge, as provided for in applicable legislation, and may be viewed and downloaded on the Company's w

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox
Related News Feeds

Mentioned Entities

See how you can reach these people and organizations